{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:59:42Z","timestamp":1790701182014,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003032","name":"Association Nationale de la Recherche et de la Technologie","doi-asserted-by":"publisher","award":["CIFRE"],"award-info":[{"award-number":["CIFRE"]}],"id":[{"id":"10.13039\/501100003032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mcpdigitalhealth.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Digital Health"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.mcpdig.2026.100375","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:48:25Z","timestamp":1785271705000},"page":"100375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5951-9589","authenticated-orcid":false,"given":"Agathe","family":"Chabassier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Vittrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Binon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Scornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Josse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.mcpdig.2026.100375_bib1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.mcpdig.2026.100375_bib2","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mcpdig.2026.100375_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.mcpdig.2026.100375_bib4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","article-title":"A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans","volume":"34","author":"Sargeant","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"S4","key":"10.1016\/j.mcpdig.2026.100375_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.mcpdig.2026.100375_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.70141","article-title":"Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study","volume":"28","author":"Alissou","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"10.1016\/j.mcpdig.2026.100375_bib7","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.3390\/jcm14155434","article-title":"Once-weekly semaglutide improves body composition in Spanish obese adults with type 2 diabetes: a 48-week prospective real-life study","volume":"14","author":"Caballero-Mateos","year":"2025","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.mcpdig.2026.100375_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.mcpdig.2026.100375_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.15439\/2018F378","article-title":"Challenges in causal inference from personal monitoring devices","volume":"16","author":"Wiktorski","year":"2018","journal-title":"Ann Comput Sci Inform Syst"},{"key":"10.1016\/j.mcpdig.2026.100375_bib10","series-title":"Causal inference on distribution functions","author":"Lin","year":"2022"},{"key":"10.1016\/j.mcpdig.2026.100375_bib11","series-title":"Proceedings of the 27th International Conference on Artificial Intelligence and Statistics","first-page":"3340","article-title":"Interpretable causal inference for analyzing wearable, sensor, and distributional data","author":"Katta","year":"2024"},{"key":"10.1016\/j.mcpdig.2026.100375_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2147\/VHRM.S350006","volume":"18","author":"Topouchian","year":"2022","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.mcpdig.2026.100375_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2147\/VHRM.S413195","volume":"19","author":"Hakobyan","year":"2023","journal-title":"Vasc Health Risk Manag"},{"issue":"470","key":"10.1016\/j.mcpdig.2026.100375_bib14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1198\/016214504000001745","article-title":"Functional data analysis for sparse longitudinal data","volume":"100","author":"Yao","year":"2005","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.mcpdig.2026.100375_bib15","series-title":"Statistics for Innovation III","first-page":"248","article-title":"Fostering drug repurposing using observational data by integrating functional data analysis and causal inference","author":"Fontana","year":"2025"},{"issue":"1","key":"10.1016\/j.mcpdig.2026.100375_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jrsssc\/qlad092","article-title":"Causal inference with a functional outcome","volume":"73","author":"Ecker","year":"2024","journal-title":"J R Stat Soc Ser C Appl Stat"},{"key":"10.1016\/j.mcpdig.2026.100375_bib17","series-title":"Doubly-robust functional average treatment effect estimation","author":"Testa","year":"2025"},{"key":"10.1016\/j.mcpdig.2026.100375_bib18","series-title":"Generic machine learning inference on heterogeneous treatment effects in randomized experiments, with an application to immunization in India","author":"Chernozhukov","year":"2018"},{"issue":"1","key":"10.1016\/j.mcpdig.2026.100375_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/1479164119883986","article-title":"Seasonal variation in home blood pressure and its relationship with room temperature in patients with type 2 diabetes","volume":"17","author":"Ushigome","year":"2019","journal-title":"Diab Vasc Dis Res"},{"issue":"2","key":"10.1016\/j.mcpdig.2026.100375_bib20","article-title":"Walking for hypertension","volume":"2","author":"Lee","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mcpdig.2026.100375_bib21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/HYPERTENSIONAHA.115.06853","article-title":"Effects of different dietary interventions on blood pressure","volume":"67","author":"Gay","year":"2016","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.mcpdig.2026.100375_bib22","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.mcpdig.2026.100375_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mcpdig.2026.100375_bib24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/02537176221101996","article-title":"Intent-to-treat (ITT) vs completer or per-protocol analysis in randomized controlled trials","volume":"44","author":"Andrade","year":"2022","journal-title":"Indian J Psychol Med"},{"issue":"10022","key":"10.1016\/j.mcpdig.2026.100375_bib25","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"10285","key":"10.1016\/j.mcpdig.2026.100375_bib26","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mcpdig.2026.100375_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/obr.12143","article-title":"Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule","volume":"15","author":"Heymsfield","year":"2014","journal-title":"Obes Rev"},{"key":"10.1016\/j.mcpdig.2026.100375_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1240263","article-title":"Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study","volume":"14","author":"Volpe","year":"2023","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.mcpdig.2026.100375_bib29","article-title":"Predicting engagement patterns with connected wearable devices in a health system: survival analysis","volume":"27","author":"Clark","year":"2025","journal-title":"J Med Internet Res"}],"container-title":["Mayo Clinic Proceedings: Digital Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949761226000416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949761226000416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:13:30Z","timestamp":1790698410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949761226000416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2949761226000416"],"URL":"https:\/\/doi.org\/10.1016\/j.mcpdig.2026.100375","relation":{},"ISSN":["2949-7612"],"issn-type":[{"value":"2949-7612","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Digital Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcpdig.2026.100375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}],"article-number":"100375"}}